Which antipsychotics have the greatest risk of dyslipidemia?

Which antipsychotics have the greatest risk of dyslipidemia?

• A. Dyslipidemia risk with Clozapine and Olanzapine
• B. Dyslipidemia risk with Quetiapine and Risperidone
• C. Dyslipidemia risk with Ziprasidone and Aripiprazole
• D. Dyslipidemia risk with Haloperidol and Lurasidone

Answer: (A)

The main idea here is how different antipsychotics differ in causing metabolic problems like dyslipidemia. Among them, clozapine and olanzapine stand out for producing the most metabolic side effects, including significant weight gain and lipid abnormalities. This combination leads to the highest risk of dyslipidemia because these drugs strongly impact metabolic pathways, often driving increases in triglycerides and cholesterol and contributing to insulin resistance. In contrast, ziprasidone and aripiprazole tend to have lower metabolic risks, with weights and lipids more likely to stay stable or even improve for some people. Quetiapine and risperidone carry a moderate risk—more than ziprasidone or aripiprazole but less than olanzapine or clozapine. Haloperidol (a typical antipsychotic) has minimal metabolic effects compared to the atypicals, and lurasidone is generally associated with a relatively favorable metabolic profile, with less weight gain and lipid impact than olanzapine or clozapine. So the combination most strongly linked to dyslipidemia is clozapine with olanzapine.

The main idea here is how different antipsychotics differ in causing metabolic problems like dyslipidemia. Among them, clozapine and olanzapine stand out for producing the most metabolic side effects, including significant weight gain and lipid abnormalities. This combination leads to the highest risk of dyslipidemia because these drugs strongly impact metabolic pathways, often driving increases in triglycerides and cholesterol and contributing to insulin resistance.

In contrast, ziprasidone and aripiprazole tend to have lower metabolic risks, with weights and lipids more likely to stay stable or even improve for some people. Quetiapine and risperidone carry a moderate risk—more than ziprasidone or aripiprazole but less than olanzapine or clozapine. Haloperidol (a typical antipsychotic) has minimal metabolic effects compared to the atypicals, and lurasidone is generally associated with a relatively favorable metabolic profile, with less weight gain and lipid impact than olanzapine or clozapine.

So the combination most strongly linked to dyslipidemia is clozapine with olanzapine.